Castle Biosciences, Inc. Stock News

The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo

Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thr

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - President, CEO, Found

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.10 per share a year ago.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTec

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AAD2024--Castle Biosciences announces it will share data across its dermatologic portfolio of gene expression profile tests at the 2024 AAD Annual Meetin

Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript

The headline numbers for Castle Biosciences, Inc. (CSTL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at three investor conferences later this month.

Although the revenue and EPS for Castle Biosciences, Inc. (CSTL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics comp

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences today announced that Derek Maetzold and Frank Stokes will present a company overview at Baird's 2023 Global Healthc

Castle reported stronger Q2 revenue growth and a lower net loss than analysts anticipated. The company also raised its full-year revenue outlook.

While the top- and bottom-line numbers for Castle Biosciences, Inc. (CSTL) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key m

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.